Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ga-Sa-DABI-4

Phase 1Small molecule

FFirst Affiliated Hospital of Chongqing Medical University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gene ExpressionRecruiting

Gene ExpressionPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Gene Expression

NCT06419361

Clinical

Trials by Indication[1]

Gene Expression1 trial

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Recruiting·FFirst Affiliated Hospital of Chongqing Medical University·Phase 1·NCT06419361·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ga-Sa-DABI-4. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ga-Sa-DABI-4 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ga-Sa-DABI-4. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Chongqing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: FFirst Affiliated Hospital of Chongqing Medical University

Related News